Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death
Sudden cardiac death is the leading cause of cardiac mortality, particularly among high-risk populations with known left ventricular systolic dysfunction. Multiple randomized clinical trials demonstrated a significant mortality benefit of the implantable cardioverter defibrillator (ICD) compared wit...
Saved in:
Published in | Cardiology clinics Vol. 26; no. 3; p. 419 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.08.2008
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | Sudden cardiac death is the leading cause of cardiac mortality, particularly among high-risk populations with known left ventricular systolic dysfunction. Multiple randomized clinical trials demonstrated a significant mortality benefit of the implantable cardioverter defibrillator (ICD) compared with antiarrhythmic drug therapy or standard medical care. Initial ICD trials showed a mortality improvement for patients who previously had experienced aborted sudden cardiac death or sustained ventricular tachycardia (secondary prevention). Primary prevention trials in selected high-risk patients who had both ischemic and nonischemic cardiomyopathy also demonstrated a mortality benefit associated with ICD treatment. More recently, cardiac resynchronization therapy with or without defibrillator capability has been shown to reduce morbidity and mortality among advanced heart failure patients with a prolonged QRS duration. |
---|---|
ISSN: | 0733-8651 |
DOI: | 10.1016/j.ccl.2008.03.006 |